EA201891651A2 - Фармацевтическая композиция для профилактики алиментарного ожирения - Google Patents

Фармацевтическая композиция для профилактики алиментарного ожирения

Info

Publication number
EA201891651A2
EA201891651A2 EA201891651A EA201891651A EA201891651A2 EA 201891651 A2 EA201891651 A2 EA 201891651A2 EA 201891651 A EA201891651 A EA 201891651A EA 201891651 A EA201891651 A EA 201891651A EA 201891651 A2 EA201891651 A2 EA 201891651A2
Authority
EA
Eurasian Patent Office
Prior art keywords
obesity
prevention
composition
pharmaceutical composition
alimentary obesity
Prior art date
Application number
EA201891651A
Other languages
English (en)
Other versions
EA201891651A3 (ru
Inventor
Анкит Шиам Сингх
Ведпракаш Мишра
Неелима Тонгра
Original Assignee
Фримлайн Прайвет Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фримлайн Прайвет Лимитед filed Critical Фримлайн Прайвет Лимитед
Publication of EA201891651A2 publication Critical patent/EA201891651A2/ru
Publication of EA201891651A3 publication Critical patent/EA201891651A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции/составу для профилактики алиментарного ожирения. Более конкретно, изобретение относится к композиции/составу, содержащему синергетическую комбинацию олеоилэтаноламида (ОЭА) и других натуральных ингредиентов, который может быть применен для лечения ожирения и сопутствующих ему нарушений, связанных с жировым обменом, таких как неалкогольный стеатогепатит (НАСГ), неалкогольная жировая болезнь печени (НАЖБП). Оно также может быть полезно при борьбе с ожирением путем поддержания веса тела. Изобретением также обеспечены различные составы и способы их получения.
EA201891651A 2017-08-19 2018-08-16 Фармацевтическая композиция для профилактики алиментарного ожирения EA201891651A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721029447 2017-08-19

Publications (2)

Publication Number Publication Date
EA201891651A2 true EA201891651A2 (ru) 2019-02-28
EA201891651A3 EA201891651A3 (ru) 2019-05-31

Family

ID=63244444

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891651A EA201891651A3 (ru) 2017-08-19 2018-08-16 Фармацевтическая композиция для профилактики алиментарного ожирения

Country Status (18)

Country Link
US (1) US10702487B2 (ru)
EP (1) EP3443987B1 (ru)
CA (1) CA3012675C (ru)
CY (1) CY1124010T1 (ru)
DK (1) DK3443987T3 (ru)
EA (1) EA201891651A3 (ru)
ES (1) ES2864136T3 (ru)
HR (1) HRP20210466T1 (ru)
HU (1) HUE053678T2 (ru)
LT (1) LT3443987T (ru)
MY (1) MY177974A (ru)
PH (1) PH12018000207A1 (ru)
PL (1) PL3443987T3 (ru)
PT (1) PT3443987T (ru)
RS (1) RS61628B1 (ru)
SG (1) SG10201806472SA (ru)
SI (1) SI3443987T1 (ru)
UA (1) UA122710C2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041495A2 (en) * 2019-08-26 2021-03-04 The Trustees Of Indiana University Method to maintain or enhance tissue
CN111084301B (zh) * 2019-12-30 2023-08-22 内江师范学院 一种桑叶提取物鱼饲料粘合剂及制备方法和应用
CN113712206A (zh) * 2021-09-16 2021-11-30 湖南希尔天然药业有限公司 一种含有桑叶dnj和桑叶肽的组合物及其制备方法
CA3242396A1 (en) * 2021-12-13 2023-06-22 The Regents Of The University Of California Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide
WO2023250211A2 (en) * 2022-06-24 2023-12-28 Veroscience Llc Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042687A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of treating obesity by the oral administration of a predigested protein composition
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
CA2442683A1 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
AU2003296895A1 (en) 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
WO2004045307A2 (en) 2002-11-18 2004-06-03 Natural Asa Dietry supplements and foods product comprising oleylethanolamide
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EP1677780A4 (en) 2003-10-16 2007-05-02 Univ California DIETETIC COMPOSITIONS AND OTHER COMPOSITIONS, COMPOUNDS AND METHODS FOR ORGANIC LIPID REDUCTION, APPETILE CONTROL, AND METABOLISM MODULATION OF FATTY ACIDS
US20090054526A1 (en) 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
WO2009093737A1 (ja) * 2008-01-25 2009-07-30 Kobayashi Pharmaceutical Co., Ltd. 抗肥満用医薬組成物
MX2010012682A (es) 2008-05-19 2010-12-15 Nestec Sa Metodos para reducir la absorcion de lipidos por un animal.
WO2012015704A2 (en) 2010-07-28 2012-02-02 The Regents Of The University Of California Peripherally restricted faah inhibitors
WO2012090225A2 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
BR112013028723A2 (pt) 2011-05-10 2016-08-09 Nestec Sa métodos e composições para promover o crescimento da massa corporal magra
MX354772B (es) 2011-08-19 2018-03-21 Univ California Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.
CN102579414A (zh) 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
DK2890684T3 (en) 2012-07-24 2018-05-07 Bial Portela & Ca Sa URINARY COMPOUNDS AND THEIR USE AS ENZYMINE INHIBITORS
WO2014037546A1 (en) 2012-09-07 2014-03-13 Nestec S.A. Oleoylethanolamide compositions
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
RU2693457C2 (ru) 2013-07-18 2019-07-03 Фондацьоне Иституто Итальяно Ди Текнолоджия Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr)
HUE033615T2 (hu) 2013-07-24 2017-12-28 Bial - Portela & Ca S A Imidazol-karboxamidok, és FAAH inhibitorként történõ alkalmazásuk
CN105593226A (zh) 2013-08-01 2016-05-18 比亚尔-珀特拉和Ca股份公司 脲类化合物及其作为faah酶抑制剂的用途
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
IL305528A (en) 2015-05-21 2023-10-01 Scisparc Ltd Combinations of opioids and acylethnoamines
WO2017025588A1 (en) 2015-08-11 2017-02-16 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound

Also Published As

Publication number Publication date
PH12018000207B1 (en) 2019-06-03
CA3012675A1 (en) 2019-02-19
EA201891651A3 (ru) 2019-05-31
PT3443987T (pt) 2021-03-18
CA3012675C (en) 2021-06-15
CY1124010T1 (el) 2022-05-27
PH12018000207A1 (en) 2019-06-03
BR102018016746A2 (pt) 2019-03-26
MY177974A (en) 2020-09-28
BR102018016746A8 (pt) 2023-02-14
EP3443987A1 (en) 2019-02-20
LT3443987T (lt) 2021-04-26
RS61628B1 (sr) 2021-04-29
SG10201806472SA (en) 2019-03-28
EP3443987B1 (en) 2020-12-23
PL3443987T3 (pl) 2021-08-02
HRP20210466T1 (hr) 2021-05-14
SI3443987T1 (sl) 2021-07-30
UA122710C2 (uk) 2020-12-28
US20190054046A1 (en) 2019-02-21
US10702487B2 (en) 2020-07-07
DK3443987T3 (da) 2021-03-22
ES2864136T3 (es) 2021-10-13
HUE053678T2 (hu) 2021-07-28

Similar Documents

Publication Publication Date Title
EA201891651A3 (ru) Фармацевтическая композиция для профилактики алиментарного ожирения
NZ729290A (en) Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MX2018002507A (es) Metodo para la inhibicion de la absorcion de lipidos y/o la promocion de excrecion de lipidos usando d-psicosa.
CO2020010193A2 (es) Una composición farmacéutica para la anemia
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
EA033540B1 (ru) Композиция, включающая окру, для применения в уменьшении абсорбции пищевого жира
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
EA201791531A1 (ru) Натуральный подсластитель
IL284345A (en) Preparations and methods for the treatment of non-alcoholic fatty liver diseases
MX2017006639A (es) Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso.
EA201692106A1 (ru) Пищевые продукты, системы, способы и наборы для замены электролитов
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
MX2017006638A (es) Metodos y composiciones para el incremento de la masa corporal magra y minimizar la ganancia de grasa corporal y el control del peso.
PH12018000227B1 (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2017021974A3 (en) NOVEL SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECHINE TO IMPROVE BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
MX2021005669A (es) Metodos para mejorar la salud metabolica en un animal.
MX2019015712A (es) Formas cristalinas de beta-sitosterol.
MX2016012553A (es) Composiciones farmaceuticas de mazindol con metformina para perdida de peso.
MY186341A (en) Nutritional compositions containing an elevated level of inositol and uses thereof
EA201301352A1 (ru) Фармацевтическая композиция и набор для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением